Delhi Court Orders ₹290 Crore Security in Patent Battle

by

In a landmark development in India’s intellectual property (IP) litigation landscape, the Delhi High Court has directed South Korean telecom equipment maker Ace Technologies Corp. to deposit ₹290 crore as interim security in an ongoing patent infringement suit filed by Canadian company Communication Components Antenna Inc. (CCA).

The single-judge bench of Justice Saurabh Banerjee issued the order citing the need to secure the plaintiff’s interests in the absence of any mutual legal enforcement treaty between India and South Korea.

Background of the Dispute

The legal battle stems from allegations by CCA that Ace Technologies unlawfully manufactured and supplied advanced beamforming antenna systems to Reliance Jio Infocomm Ltd, violating CCA’s Indian patent covering next-generation multi-beam antenna technologies. These patented systems are critical for optimizing signal strength and reducing interference in mobile networks.

CCA claims its proprietary designs were copied by Ace and sold on a large scale to Jio, thereby infringing on its intellectual property. The plaintiff is seeking ₹1,160 crore in damages.

Court’s Observations

Justice Banerjee relied on earlier court findings and observed that a prima facie case of infringement had already been made in earlier hearings and upheld by the Division Bench and the Supreme Court of India. The court noted that Ace’s financial health had deteriorated, with a 65% drop in market capitalization, and it had no significant presence or assets in India.

These concerns led the court to invoke Section 151 of the Code of Civil Procedure, granting it inherent powers to pass any orders necessary to serve the ends of justice. The ₹290 crore deposit is in addition to the previously secured ₹75 crore, bringing the total security amount to ₹365 crore, reportedly the highest ever in an Indian patent lawsuit.

Patent at the Heart of the Case

CCA’s patent relates to beamforming antenna technology, used in cellular base stations for targeted signal delivery. The company alleges Ace’s antennas replicate these patented designs, offering similar functionality and configurations, thereby infringing on their exclusive rights.

Next Phase of the Case

The Delhi High Court has directed the parties to proceed to the recording of evidence, marking the next critical stage of the trial. The court emphasized that this financial security was crucial to ensure that the plaintiff’s claim does not become unenforceable in the future due to the defendant’s foreign status and lack of assets in India.

This article is based on publicly available information and court documents regarding the Delhi High Court’s proceedings in the patent infringement case between Communication Components Antenna Inc. and Ace Technologies Corp. The details presented are for informational and journalistic purposes only and do not constitute legal advice or opinion. Readers are encouraged to consult official court records or legal experts for more specific interpretations.

Apple Ordered to Pay $110.7M for Patent Infringement

by

Apple Inc. has been ordered to pay $110.7 million in damages after a U.S. federal jury found the tech giant guilty of infringing a wireless communication patent owned by Spanish technology firm TOT Power Control, S.L. The case centered around a key 3G patent used in Apple’s iPhones, iPads, and Apple Watches.

The jury in Delaware federal court determined that Apple had violated U.S. Patent No. 7,532,865, which relates to outer loop power control technology, crucial for improving efficiency in mobile device communication networks. It helps to manage signal strength between a mobile device and network base stations.

What the Verdict Means

The decision follows a lengthy trial in which TOT Power Control alleged that Apple used its patented technology without proper licensing agreements. The awarded amount reflects a running royalty of approximately $0.25 per device that uses the infringing technology, covering a vast range of Apple products operating with 3G capability.

TOT Power Control is a Spain-based intellectual property firm established by inventor and engineer Álvaro López-Medrano. The company focuses on essential wireless communication technologies and has been actively defending its IP rights globally.

Apple responded to the verdict with disappointment, stating it will pursue an appeal. The company has a long history of defending itself in patent infringement suits, particularly around standard-essential patents (SEPs)—those considered fundamental to wireless communication standards like 3G, 4G, and 5G.

Pattern of Patent Disputes for Apple

This ruling adds to a string of legal challenges Apple is currently facing related to SEPs:

In May 2025, a UK court ordered Apple to pay £402 million (approximately $502 million) to Optis Cellular Technology in a separate 4G patent dispute.

In another U.S. case involving Optis, Apple had a $300 million jury verdict overturned after a federal appeals court ruled there were errors in jury instructions.

These cases reflect ongoing tensions between major tech companies and patent holders over FRAND terms—agreements that require essential patent licensing to be fair, reasonable, and non-discriminatory.

Legal and Industry Implications

The ruling reinforces the importance of upholding SEP licensing terms, especially as global tech firms continue to leverage wireless standards in their devices. Analysts suggest the outcome could embolden more patent holders to litigate, particularly in the U.S., where damages can scale significantly.

While $110 million is a modest sum for Apple—whose annual revenues exceed $380 billion—it underscores the financial risks associated with failing to secure or honor licensing deals for standard wireless technologies.

The case also highlights the growing assertiveness of non-U.S. companies, like TOT Power Control, in pursuing patent enforcement across international jurisdictions.

This article is based on publicly available news sources and legal filings related to the Apple vs TOT Power Control patent case. All facts have been verified as of the time of publication. This article is intended for informational purposes only and does not constitute legal or financial advice.

Samsung Faces Legal Battle for Alleged eSIM Patent Violations

by

In a significant development in the world of intellectual property and telecommunications, Network-1 Technologies, Inc. (NYSE: NTIP) has initiated a patent infringement lawsuit against Samsung Electronics Co., Ltd. and Samsung Electronics America, Inc. The suit was filed in the U.S. District Court for the Eastern District of Texas, a jurisdiction known for handling complex patent litigation.

The case revolves around Samsung’s alleged unauthorized use of Network-1’s eSIM and 5G authentication technologies in a wide range of its mobile devices, including smartphones, tablets, and smartwatches.

🔍 Allegations and Patent Details

Network-1 asserts that six U.S. patents from its M2M/IoT (Machine-to-Machine/Internet of Things) portfolio are being violated. These patents—acquired by Network-1 in December 2017—are said to cover core authentication and secure communication technologies used in eSIM-based mobile devices.

The patents in question are expected to remain valid until 2033–2034, placing them well within their enforceable lifespan.

The complaint alleges that Samsung incorporated these patented technologies into its Galaxy series of devices without obtaining a proper license, thereby violating Network-1’s intellectual property rights.

📈 Market Relevance and Timing

The timing of the lawsuit is strategic. According to the Trusted Connectivity Alliance, more than 500 million eSIM-capable devices were shipped globally in 2024 alone—a 56% rise in eSIM profile downloads from the previous year. Samsung is a major player in this fast-growing market.

With the rapid expansion of 5G and eSIM adoption, Network-1’s patented technologies play a critical role in ensuring secure authentication and connectivity—making them highly valuable in today’s mobile device ecosystem.

🧠 About Network-1 Technologies

Network-1 is a well-known intellectual property licensing company that specializes in acquiring and enforcing technology patents. The company does not manufacture products but focuses on monetizing its IP assets through licensing and litigation.

Their M2M/IoT patent portfolio includes:

41 U.S. patents

15 international patents

25 pending applications globally

⚖️ Legal Strategy and Implications

Filing in the Eastern District of Texas—a patent-holder-friendly court—could give Network-1 a strategic advantage. Samsung, on the other hand, is expected to vigorously defend its position, potentially challenging the validity, enforceability, or scope of the patents.

Legal experts suggest that if Network-1 prevails, it could result in:

A licensing agreement worth millions

Monetary damages

A possible injunction against the sale of infringing devices

Given the global scale of Samsung’s product distribution, the outcome of this case could have far-reaching consequences for both parties.

🔮 What’s Next?

Both parties are likely to engage in extensive pre-trial activities, including evidence discovery and expert testimony. The tech industry will be closely watching the case, which could reshape licensing norms in the high-growth sectors of 5G, IoT, and mobile security.

Delhi High Court Blocks Unauthorized Streaming of India Tour 2025

by

In a landmark ruling, the Delhi High Court has granted a Dynamic+ injunction in favor of JioCinema and Disney+ Hotstar, blocking unauthorized streaming of the highly anticipated India Tour of England 2025.

Court Recognizes Clear Copyright Violation

Justice Sanjeev Narula of the Delhi High Court acknowledged that unauthorized streaming platforms were blatantly infringing copyright by broadcasting the live cricket series without permission. The court classified this as a “clear example of copyright infringement.”

The rights for the digital broadcast of the series are held exclusively by JioCinema and Disney+ Hotstar, through Viacom18 and Star India respectively.

What Is a Dynamic+ Injunction?

The Dynamic+ injunction allows rights holders to immediately block new rogue domains that illegally stream the matches, without needing to approach the court repeatedly. This proactive measure ensures that pirates can’t bypass bans by simply changing URLs or creating mirror sites.

The court emphasized that such swift actions are essential in dealing with the “menace of online piracy,” particularly during live sports broadcasts, where real-time viewership is commercially critical.

45 Rogue Websites Already Blocked

The order has already resulted in the blocking of over 45 pirate websites. Internet Service Providers (ISPs) have been directed to disable access to these domains.

Industry Applauds Ruling

The decision has been welcomed by broadcasters and content creators, who have long demanded stricter enforcement mechanisms against digital piracy.

A spokesperson from Viacom18 said, “This ruling protects our significant investments in sports content and sends a strong message to digital pirates.”

This article is based on publicly available information and legal filings. It does not constitute legal advice. All names, trademarks, and brands mentioned belong to their respective owners

Court Rules in Favor of WEE POWER Trademark Over Ferrari

by

In a significant legal decision, the Kuala Lumpur High Court has ruled in favor of Sunrise-Mark Sdn Bhd, a Malaysian company that produces the energy drink WEE POWER, in a trademark dispute brought by luxury Italian carmaker Ferrari SpA.

Ferrari alleged that the WEE POWER logo, which features two rearing horses on either side of a prominent “W”, bore too close a resemblance to Ferrari’s iconic single rearing horse emblem, potentially misleading consumers and damaging Ferrari’s brand identity. However, the court dismissed these claims, stating that the trademarks are distinct in design, context, and usage.

Case Overview

The dispute arose when Sunrise-Mark applied to register the WEE POWER trademark in Malaysia. Ferrari objected, arguing that the drink’s branding, particularly the horse imagery, could cause brand confusion and infringe upon Ferrari’s intellectual property.

The court, however, found the argument to be without sufficient basis. Presiding judge Justice Wong Kian Kheong highlighted that while both logos contain horse figures, their visual representation and overall branding are clearly distinguishable.

Court’s Findings

In the detailed judgment, the court noted several key differences:

Logo Structure: Ferrari’s emblem is a solitary horse standing on its hind legs, a symbol tightly associated with its automotive legacy. In contrast, WEE POWER’s mark features two horses, each facing inward with a stylized “W” at the center and the words “WEE POWER” below.

Sector Disparity: Ferrari is a luxury automobile brand, while Sunrise-Mark produces consumer beverages. The judge stated that it is unlikely any reasonable consumer would associate an energy drink with a supercar manufacturer.

Meaning of “WEE”: The name “WEE” was accepted by the court as being derived from the name of the company’s founder, Wee Juan Chien, rather than an attempt to imitate or draw attention through the use of the English word.

Due to these factors, the court ruled there was no risk of public confusion nor evidence of any intention by Sunrise-Mark to exploit Ferrari’s brand image.

Sunrise-Mark Can Proceed with Trademark

As a result of the decision, Sunrise-Mark is now legally permitted to register and use the WEE POWER logo in Malaysia. The court also ordered Ferrari to bear the legal costs of the proceedings, solidifying the judgment in favor of the Malaysian company.

Company Reactions

Sunrise-Mark issued a statement celebrating the decision as a win for local entrepreneurs and fair competition. The company emphasized that its branding was designed independently and intended to reflect its identity, not to mimic or capitalize on any global trademarks.

Ferrari has not yet released an official statement regarding the ruling or whether it plans to appeal.

Implications of the Ruling

This case highlights the boundaries of trademark protection, especially when large international brands attempt to challenge local firms in unrelated sectors. The decision reinforces that context, industry, and branding clarity are critical in determining trademark conflicts.

This article is for informational purposes only and is based on publicly available reports as of June 2025. It does not offer legal advice. All brand names and logos mentioned are the property of their respective owners.

Japan Grants Patent for Non-Invasive Endometriosis Test

by

Proteomics International Laboratories Ltd (ASX: PIQ), a global leader in predictive diagnostics, has announced that it has been granted its first patent in Japan for Pro marker Endo—a world-first, non-invasive blood test developed to diagnose endometriosis. This strategic patent grant represents a major milestone in the company’s global intellectual property (IP) rollout and sets the stage for accelerated commercialization across key markets.

Groundbreaking Diagnostic Solution

Endometriosis is a chronic inflammatory condition affecting roughly 1 in 9 women of reproductive age, characterized by the growth of tissue similar to the uterine lining outside the uterus. It causes severe pelvic pain, infertility, and impacts mental and physical well-being. Current diagnostic methods—mainly laparoscopic surgery—are invasive, expensive, and result in diagnostic delays of 7 to 10 years on average.

PromarkerEndo offers a revolutionary alternative. Using a simple blood sample, the test applies a biomarker-based algorithm to detect the presence of endometriosis and deliver results in the form of a “traffic light” system:

Green: Low likelihood of endometriosis

Amber: Moderate likelihood

Red: High likelihood

This intuitive format provides clinicians with actionable insights, greatly improving early-stage detection and treatment planning.

Strong Clinical Results

The PromarkerEndo test has demonstrated outstanding clinical performance in both research and real-world settings. Results from a landmark clinical study involving 704 participants—recently presented at the 16th World Congress on Endometriosis (May 2025)—highlighted the test’s exceptional diagnostic accuracy. The area under the curve (AUC), a measure of diagnostic performance, ranged from 0.89 to 0.94, particularly excelling in early-stage (I-II) detection.

These outcomes surpass many traditional diagnostic approaches and emphasize the test’s utility as a first-line screening tool in both primary and specialist care.

Strategic Importance of the Japanese Patent

The patent granted by the Japan Patent Office significantly enhances Proteomics International’s global IP portfolio. Japan, with a population of over 125 million and an advanced healthcare system, represents a high-value market for women’s health diagnostics. The new patent strengthens the company’s freedom to operate in Asia and supports upcoming commercial launches.

Proteomics International now holds patents or patent applications for PromarkerEndo in Australia, China, Europe, and the United States, with the Japanese grant adding further momentum to its global rollout.

Managing Director Dr. Richard Lipscombe commented:

“The Japanese patent is a critical milestone in protecting our proprietary technology in one of the world’s most sophisticated healthcare markets. It reinforces the strength of our innovation and supports our mission to bring non-invasive, accessible diagnostics to women suffering from endometriosis worldwide.”

Path to Commercialization

Proteomics International is actively working towards the initial commercial launch of PromarkerEndo in Australia by Q3 2025, with other markets such as Japan, the EU, and the U.S. expected to follow. The company is in discussions with diagnostic partners and health providers to integrate PromarkerEndo into standard clinical pathways.

The potential market for the test is vast. With endometriosis affecting over 190 million women globally, and with growing public and clinical awareness, demand for improved diagnostics is surging.

Broader Implications

Beyond offering a non-invasive alternative to laparoscopy, PromarkerEndo has the potential to reshape how healthcare systems approach chronic women’s health conditions. By enabling earlier diagnosis:

Patient outcomes can improve dramatically

Healthcare costs associated with delayed diagnosis and invasive procedures may be reduced

Physicians gain a powerful tool for faster triage and referral

Additionally, this development aligns with global policy shifts focused on addressing historical gaps in women’s health research and diagnostics.

Conclusion

The Japanese patent marks a crucial step forward for Proteomics International and its pioneering PromarkerEndo test. With clinical validation, global IP protection, and a clear path to market, the company is well-positioned to transform endometriosis diagnosis—bringing hope to millions of women who have long faced delays, misdiagnosis, and inadequate care

🔖 Disclaimer:

This article is based on publicly available information provided by Proteomics International Laboratories and related sources.

Nikon’s Game-Changing Sensor for Filmmaking

by

Nikon’s latest innovation may change the future of filmmaking. The company has filed a new Japanese patent revealing a sensor capable of capturing both infrared (IR) and visible light. This new image sensor is designed specifically for cinema applications, opening doors for filmmakers to explore new creative possibilities.

📸 The Technology Behind the Patent

The patent introduces a multi-layer image sensor that can record infrared and visible spectrum data at the same time. Traditionally, filmmakers had to use external filters or multiple camera systems to achieve this. Nikon’s new sensor design removes that need.

By integrating the layers, Nikon’s sensor may capture IR and RGB information in a single frame. This could benefit cinematic storytelling, especially in stylized shoots, surveillance scenes, or night-for-day setups.

🎥 Why It Matters for Filmmakers

Creative Flexibility: With both types of data available, colorists and editors gain more control in post-production.

Efficiency on Set: Filmmakers can shoot with one camera setup, saving time and money.

Stylized Cinematic Looks: IR imagery offers surreal visual effects. It can enhance foliage, skin tones, and lighting in unique ways.

Advanced Filmmaking Tools: The sensor may also support better tracking and autofocus in challenging lighting conditions.

🛠️ Current Limitations

While the patent is promising, it remains in the conceptual stage. There’s no confirmation yet on whether or when this technology will reach Nikon’s product line. Developing a dual-layer sensor that balances image quality, light sensitivity, and dynamic range is complex.

📅 What’s Next?

Nikon has not made any official announcements tied to this patent. If developed commercially, this sensor could appear in Nikon’s upcoming cinema-focused cameras, potentially competing with brands like RED, ARRI, and Canon’s Cinema EOS line.

📢 Industry Buzz

The patent has already drawn attention from cinematographers and gear reviewers. Many believe Nikon is working to enter the high-end cinema camera market with cutting-edge technology.

📌 Conclusion

Nikon’s newly filed patent reveals a bold step toward hybrid IR-visible sensors for cinema applications. If successful, it could redefine how cinematographers approach lighting, editing, and storytelling.

How Indian Drugmakers Can Capitalize on Patent Expiry

by

India’s pharmaceutical industry is preparing to tap into a massive global opportunity. A patent cliff worth $63.7 billion is set to hit the U.S. drug market. Experts say Indian drugmakers are well-positioned to benefit.

What Is a Patent Cliff?

A patent cliff occurs when major drugs lose their patent protection. This allows other companies to produce generic versions. In the U.S., several blockbuster drugs are nearing the end of their exclusivity.

From 2025 to 2030, drugs worth $236 billion globally will lose patent rights. Of this, the U.S. accounts for $63.7 billion. This opens the door for generic manufacturers, especially from India.

Why Indian Pharma Has an Edge

India is a global leader in generic drug manufacturing. It supplies around 30% of generic medicines to the U.S. market.

Indian companies like Sun Pharma, Biocon, Cipla, and Lupin have FDA-approved facilities. These firms are investing in research and biosimilars to seize the moment.

They offer affordable alternatives at scale. This makes them attractive in both the U.S. and other global markets.

Analysts See Huge Potential

Analysts expect Indian firms to earn $8–10 billion annually from this patent cliff. With the right strategy, this number could grow even more.

India’s cost advantage, skilled workforce, and regulatory knowledge make it a key player in this shift.

Key Strategies for Indian Companies

Fast-track development of generics and biosimilars

File early for U.S. FDA approvals

Challenge patents through Paragraph IV filings

Form partnerships with global drug firms

Expand production to meet new demand

These steps will help Indian pharma capitalize on the coming wave of drug expiries.

Risks to Watch

While the opportunity is big, there are challenges too. These include:

Price competition

Regulatory delays

Market saturation

High development costs for biosimilars

Still, the overall outlook is positive. Indian pharma is expected to play a leading role.

Conclusion

The $63.7 billion U.S. patent cliff is a game-changer. It creates a golden chance for India’s generic and biosimilar companies. If executed well, Indian pharma could dominate the global generics space in the next five years.

📌 Disclaimer

This article is for informational purposes only. It is based on publicly available data and expert analysis.

Zen Technologies Unveils Patented Military Training Innovation

by

Zen Technologies Ltd., a leading provider of defence training and anti-drone solutions, has announced a major milestone in its innovation journey. The company has been granted a new patent for a cutting-edge technology that significantly enhances the effectiveness and reliability of laser-based military training systems.

The patent, titled “Single ILU Long Pass Filter,” is Zen Technologies’ 54th patent in India and 82nd globally. This new innovation marks a significant leap in the field of combat training, introducing an advanced optical filter that consolidates both visible and infrared laser beams into a single, stable beam for enhanced precision in simulation environments.

What Makes the Innovation Unique?

The patented Single ILU Long Pass Filter addresses one of the key limitations in current military training equipment — the frequent misalignment and maintenance issues associated with dual-laser systems. Zen’s new solution offers a compact, rugged, and maintenance-free alternative. The merged beam ensures high alignment accuracy and consistent performance, even in challenging environmental conditions.

Unlike traditional setups, this innovation eliminates the need for two separate laser emitters and a beam combiner. It simplifies the system’s design and enhances reliability — a critical advantage for mobile field simulators and rugged military training deployments.

A Step Forward in India’s Defence Tech Sector

Zen Technologies’ new patent strengthens its position as a pioneer in indigenous defence simulation technology. As India continues to focus on self-reliance in defence manufacturing through the ‘Make in India’ initiative, innovations like these are vital in reducing dependency on foreign technology and increasing export potential.

The compact and modular design of the patented filter makes it ideal for integration into a wide range of simulation systems, from portable infantry simulators to full-scale tactical training environments. This advancement aligns with Zen’s broader strategic objective of delivering state-of-the-art training solutions to armed forces both in India and internationally.

Company Milestones and Global Reach

The company has supplied over 1,000 military training systems across India and to global clients, including institutions such as the U.S. Department of Defense. With in-house R&D and manufacturing capabilities, Zen continues to push boundaries in defence simulation, anti-drone solutions, and tactical training systems.

Market Impact and Future Prospects

The announcement of this patent is expected to bolster investor confidence and further improve Zen’s standing in the defence and technology sectors. The patented filter not only reduces logistical burdens and system downtime but also enhances the realism and tactical accuracy of simulated combat scenarios.

As countries modernize their defence training infrastructure, Zen’s technology is poised to play a critical role in shaping the future of immersive, scalable, and mission-ready training systems.

Disclaimer:

This article is a news report based on publicly available information sourced from credible media outlets and Zen Technologies’ official communications. The information provided herein is for general informational purposes only and does not constitute investment advice or a solicitation to invest in any security or product.

Autonomix Medical Secures Patent for Nerve-Sensing Technology

by

Autonomix Medical, Inc. (NASDAQ: AMIX), a pioneering medtech company focused on nerve-targeted diagnostics and therapies, has been granted a U.S. patent (No. 12,279,889 B2) for its innovative catheter-based nerve-sensing and ablation technology. This marks a major milestone for the company as it continues to expand its intellectual property portfolio and progress toward commercialization.

✅ Cutting-Edge Technology Targeting Hard-to-Treat Conditions

The newly patented device combines microchip sensing arrays, microneedle sensors, optical sensors, and unique microfingers to accurately detect, map, and monitor nerve activity. It is specifically designed to locate small nerves in and around blood vessels and capture real-time electrophysiological signals before, during, and after neuromodulation or radiofrequency (RF) ablation.

This proprietary technology is aimed at addressing a range of serious health conditions linked to overactive sympathetic nervous activity, such as:

Chronic pain (including pancreatic cancer-related pain)

Hypertension

Cardiovascular diseases

Metabolic disorders

Certain neurological conditions

Autonomix’s platform may represent a transformative solution in nerve modulation, with the potential to reduce dependency on opioid-based treatments.

🧪 Next Phase: Clinical Trials in the U.S.

Backed by promising Phase I clinical data demonstrating substantial pain relief and reduced opioid use, Autonomix plans to file for an Investigational Device Exemption (IDE) with the U.S. Food and Drug Administration (FDA). Clinical trials in the United States are scheduled to commence in 2025, with an initial focus on treating pancreatic cancer pain.

While the device is still under investigation and not yet approved for commercial use, these developments underscore its strong potential in a multi-billion-dollar market.

🔒 Strengthened Intellectual Property Portfolio

The issuance of this U.S. patent significantly enhances Autonomix’s competitive standing. The company now holds over 80 patents worldwide, signaling its stronghold in the emerging market of catheter-based nerve therapies. The patent provides exclusive protection in the U.S. for its sensing and ablation system, supporting future licensing opportunities and strategic partnerships.

📉 Financial & Market Context

Despite recent market challenges—Autonomix shares have declined over 65% year-to-date—the company maintains a robust liquidity position and continues to invest in research and development. This patent milestone could serve as a catalyst for investor confidence as the company approaches critical clinical and regulatory phases.

🔍 Key Highlights

Feature Details

Patent No. US 12,279,889 B2
Technology Nerve-sensing + RF ablation catheter system
Clinical Use (Planned) Chronic pain, hypertension, cardiac, metabolic, neuro disorders
Clinical Trial Timeline IDE submission in 2025; U.S. trials to follow
Current Status Investigational; not FDA approved
IP Strength Over 80 patents issued global

📌 Disclaimer

This article is for informational purposes only.